Psychological Health in Adults with Morquio Syndrome

  • Nadia Ali
  • S. Cagle
Research Report
Part of the JIMD Reports book series (JIMD, volume 20)


Mucopolysaccharidosis type IV (MPSIV), also known as Morquio syndrome, is a progressive genetic condition which predominantly affects skeletal development. Research thus far has focused on physical manifestations, with little attention to psychological characteristics. As a first step in determining the natural occurrence of psychological symptoms in this population, we administered Achenbach measures of psychological functioning (ASEBA ASR and OASR), quality of life (SF-36), and pain severity (BPI) questionnaires to 20 adults with Morquio syndrome. 11/20 subjects (55%) scored within the symptomatic range on at least one or more ASEBA problem scales. These subjects also had higher pain severity scores (p = 0.051) and pain interference scores (p = 0.03) on the BPI. However, subjects with psychological symptoms did not differ significantly on QOL measures from those without psychological symptoms. Overall, subjects scored below the US mean only in physical health QOL (p < 0.001) on the SF-36, not mental health QOL. Implications of this study include the need for greater attention to psychological health in persons with Morquio syndrome, including regular assessment for psychological symptoms in addition to the quality of life measures typically used, as the latter may miss important information. Greater attention to psychological symptoms may help maximize overall health in adults with Morquio syndrome. Comparison with psychological studies on other lysosomal storage diseases suggests these results may be disease specific, rather than the result of living with chronic pain or having an LSD in general.


Morquio Mucopolysaccharidosis Psychological health Quality of life 



Achenbach system of empirically based assessment


Adult self-report


Brief pain inventory


Lysosomal storage disease




Older adult self-report


Pain interference


Pain severity


Quality of life


Social-adaptive functioning



The authors thank John Hanfelt in the Emory University Department of Biostatistics and Bioinformatics in the Rollins school of Public Health for his assistance with statistical analysis. They also thank all the individuals who participated in this study for being willing to share their lives and experiences for the sake of increasing knowledge about Morquio syndrome.

Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


  1. Achenbach TM, Rescorla LA (2003) Manual for the ASEBA adult forms and profiles. University of Vermont, Research Center for Children, Youth, and Families, Burlington, VT,
  2. Bax MC, Colville GA (1995) Behaviour in mucopolysaccharide disorders. Arch Dis Child 73:77–81CrossRefPubMedCentralPubMedGoogle Scholar
  3. Bolsover FE, Murphy E, Cipolotti L, Werring DJ, Lachmann RH (2014) Cognitive dysfunction and depression in Fabry disease: a systemic review. J Inherit Metab Dis 37(2):177–187CrossRefPubMedGoogle Scholar
  4. Cleeland CS (2009) The brief pain inventory user guide. MD Anderson Cancer Center, Houster, TXGoogle Scholar
  5. Cleeland CS, Ryan KM (1994) Pain assessment: global use of the brief pain inventory. Ann Acad Med Singapore 23:129–138PubMedGoogle Scholar
  6. Cole AL, Lee PJ, Hughes DA, Deegan PB, Waldeck S, Lachmann RH (2007) Depression in adults with Fabry disease: a common and underdiagnosed problem. J Inherit Metab Dis 30:943–951CrossRefPubMedGoogle Scholar
  7. Crosbie TW, Packman W, Packman S (2009) Psychological aspects of patients with Fabry disease. J Inherit Metab Dis 32:745–753CrossRefPubMedGoogle Scholar
  8. Davison JE, Kearney S, Horton J et al (2012) Intellectual and neurological functioning in Morquio syndrome (MPS IVA). J Inhert Metab Dis 36(2):323–328CrossRefGoogle Scholar
  9. Gold KF, Pastores GM, Botteman MF et al (2002) Quality of life of patients with Fabry disease. Qual Life Res 11:317–327CrossRefPubMedGoogle Scholar
  10. Grewal RP (1993) Psychiatric disorders in patients with Fabry’s disease. Int J Psychiatry Med 23:307–312CrossRefPubMedGoogle Scholar
  11. Hendriksz C, Lavery C, Coker M et al (2014) Burden of disease in patients with Morquio A syndrome: results from an international patient-reported outcomes survey. Orphanet J Rare Dis 9:32CrossRefPubMedCentralPubMedGoogle Scholar
  12. Hoffmann B, Garcia de Lorenzo A, Mehta A et al (2005) Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey). J Med Genet 42:247–252CrossRefPubMedCentralPubMedGoogle Scholar
  13. Katon W, Russo J, Lin EH et al (2009) Diabetes and poor disease control: is comorbid depression associated with poor medication adherence or lack of treatment intensification? Psychosom Med 71(9):965–972CrossRefPubMedCentralPubMedGoogle Scholar
  14. Khawaja IS, Westermeyer JJ, Gajwani P, Feinstein RE (2009) Depression and coronary artery disease: the association, mechanisms, and therapeutic implications. Psychiatry (Edgmont) 6:38–51Google Scholar
  15. Kuratsubo I, Suzuki Y, Orii KO et al (2009) Psychological status of patients with Mucopolysaccharidosis type II and their parents. Pediatr Int 51:41–47CrossRefPubMedGoogle Scholar
  16. Laney DA, Gruskin DJ, Fernhoff PM et al (2010) Social-adaptive and psychological functioning of patients affected by Fabry disease. J Inherit Metab Dis 33(Suppl 3):S73–S81CrossRefPubMedGoogle Scholar
  17. Maruish ME, DeRosa MA (2009) A guide to the integration of certified Short Form survey scoring and data quality evaluation capabilities. QualityMetric Incorporated, Lincoln, RIGoogle Scholar
  18. Maruish ME, Kosinski M (2009) A guide to the development of certified Short Form interpretation and reporting capabilities. QualityMetric Incorporated, Lincoln, RIGoogle Scholar
  19. Masek BJ, Sims KB, Bove CM, Korson MS, Short P, Norman DK (1999) Quality of life assessment in adults with type 1 Gaucher disease. Qual Life Res 8:263–268CrossRefPubMedGoogle Scholar
  20. Northover H, Cowie RA, Wraith JE (1996) Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J Inherit Metab Dis 19(3):357–365CrossRefPubMedGoogle Scholar
  21. Packman W, Crosbie TW, Riesner A, Fairley C, Packman S (2006) Psychological complications of patients with Gaucher disease. J Inherit Metab Dis 29:99–105CrossRefPubMedGoogle Scholar
  22. Tomatsu S, Montano AM, Oikawa H et al (2011) Mucopolysaccaridosis type IVA (Morquio A disease): clinical review and current treatment: a special review. Curr Pharm Biotechnol 12(6):931–945CrossRefPubMedGoogle Scholar
  23. Wang RY, Lelis A, Mirocha J, Wilcox WR (2007) Heterozygous Fabry women are not just carriers, but have a significant burden of disease and impaired quality of life. Genet Med 9(1):34–45CrossRefPubMedGoogle Scholar
  24. Watt T, Burlina AP, Cazzorla C et al (2010) Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: findings from the Fabry registry. Genet Med 12:703–712CrossRefPubMedGoogle Scholar
  25. Weinreb N, Barranger J, Packman S et al (2007) Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease. Clin Genet 71(6):576–588CrossRefPubMedGoogle Scholar
  26. Wilcox WR, Oliveira JP, Hopkin RJ et al (2008) Females with Fabry disease frequently have major organ involvement: lessons from the Fabry Registry. Mol Genet Metab 93:112–128CrossRefPubMedGoogle Scholar

Copyright information

© SSIEM and Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  1. 1.Department of Human GeneticsEmory UniversityAtlantaUSA

Personalised recommendations